• Je něco špatně v tomto záznamu ?

Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria

I. Bereczki, V. Vimberg, E. Lőrincz, H. Papp, L. Nagy, S. Kéki, G. Batta, A. Mitrović, J. Kos, Á. Zsigmond, I. Hajdú, Z. Lőrincz, D. Bajusz, L. Petri, J. Hodek, F. Jakab, GM. Keserű, J. Weber, L. Naesens, P. Herczegh, A. Borbás

. 2022 ; 12 (1) : 16001. [pub] 20220926

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024353

Grantová podpora
P4-0127 Javna Agencija za Raziskovalno Dejavnost RS (Slovenian Research Agency)
NKP- 21-5 Hungarian Academy of Sciences
201832-30 and 202135-30 Fundació La Marató de TV3 (TV3 Marathon Foundation)
K 132870 Hungarian Scientific Research Fund

Patients infected with SARS-CoV-2 risk co-infection with Gram-positive bacteria, which severely affects their prognosis. Antimicrobial drugs with dual antiviral and antibacterial activity would be very useful in this setting. Although glycopeptide antibiotics are well-known as strong antibacterial drugs, some of them are also active against RNA viruses like SARS-CoV-2. It has been shown that the antiviral and antibacterial efficacy can be enhanced by synthetic modifications. We here report the synthesis and biological evaluation of seven derivatives of teicoplanin bearing hydrophobic or superbasic side chain. All but one teicoplanin derivatives were effective in inhibiting SARS-CoV-2 replication in VeroE6 cells. One lipophilic and three perfluoroalkyl conjugates showed activity against SARS-CoV-2 in human Calu-3 cells and against HCoV-229E, an endemic human coronavirus, in HEL cells. Pseudovirus entry and enzyme inhibition assays established that the teicoplanin derivatives efficiently prevent the cathepsin-mediated endosomal entry of SARS-CoV-2, with some compounds inhibiting also the TMPRSS2-mediated surface entry route. The teicoplanin derivatives showed good to excellent activity against Gram-positive bacteria resistant to all approved glycopeptide antibiotics, due to their ability to dually bind to the bacterial membrane and cell-wall. To conclude, we identified three perfluoralkyl and one monoguanidine analog of teicoplanin as dual inhibitors of Gram-positive bacteria and SARS-CoV-2.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024353
003      
CZ-PrNML
005      
20221031100302.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-022-20182-y $2 doi
035    __
$a (PubMed)36163239
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bereczki, Ilona $u Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary $u National Laboratory of Virology, University of Pécs, Pecs, Ifjúság útja 20, 7624, Hungary
245    10
$a Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria / $c I. Bereczki, V. Vimberg, E. Lőrincz, H. Papp, L. Nagy, S. Kéki, G. Batta, A. Mitrović, J. Kos, Á. Zsigmond, I. Hajdú, Z. Lőrincz, D. Bajusz, L. Petri, J. Hodek, F. Jakab, GM. Keserű, J. Weber, L. Naesens, P. Herczegh, A. Borbás
520    9_
$a Patients infected with SARS-CoV-2 risk co-infection with Gram-positive bacteria, which severely affects their prognosis. Antimicrobial drugs with dual antiviral and antibacterial activity would be very useful in this setting. Although glycopeptide antibiotics are well-known as strong antibacterial drugs, some of them are also active against RNA viruses like SARS-CoV-2. It has been shown that the antiviral and antibacterial efficacy can be enhanced by synthetic modifications. We here report the synthesis and biological evaluation of seven derivatives of teicoplanin bearing hydrophobic or superbasic side chain. All but one teicoplanin derivatives were effective in inhibiting SARS-CoV-2 replication in VeroE6 cells. One lipophilic and three perfluoroalkyl conjugates showed activity against SARS-CoV-2 in human Calu-3 cells and against HCoV-229E, an endemic human coronavirus, in HEL cells. Pseudovirus entry and enzyme inhibition assays established that the teicoplanin derivatives efficiently prevent the cathepsin-mediated endosomal entry of SARS-CoV-2, with some compounds inhibiting also the TMPRSS2-mediated surface entry route. The teicoplanin derivatives showed good to excellent activity against Gram-positive bacteria resistant to all approved glycopeptide antibiotics, due to their ability to dually bind to the bacterial membrane and cell-wall. To conclude, we identified three perfluoralkyl and one monoguanidine analog of teicoplanin as dual inhibitors of Gram-positive bacteria and SARS-CoV-2.
650    _2
$a antibakteriální látky $x chemie $7 D000900
650    _2
$a antivirové látky $x chemie $7 D000998
650    12
$a COVID-19 $7 D000086382
650    _2
$a kathepsiny $x farmakologie $7 D002403
650    12
$a fluorokarbony $x farmakologie $7 D005466
650    _2
$a glykopeptidy $x chemie $7 D006020
650    _2
$a grampozitivní bakterie $7 D006094
650    _2
$a lidé $7 D006801
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a teikoplanin $x farmakologie $7 D017334
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vimberg, Vladimir $u Laboratory for Biology of Secondary Metabolism, Institute of Microbiology, Academy of Sciences of the Czech Republic, BIOCEV, Průmyslová 595, 252 50, Vestec, Czech Republic
700    1_
$a Lőrincz, Eszter $u Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary $u Institute of Healthcare Industry, University of Debrecen, Debrecen, Nagyerdei körút 98, 4032, Hungary $u Doctoral School of Pharmaceutical Sciences, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary
700    1_
$a Papp, Henrietta $u National Laboratory of Virology, University of Pécs, Pecs, Ifjúság útja 20, 7624, Hungary $u Faculty of Sciences, Institute of Biology, University of Pécs, Pecs, Ifjúság útja 6, 7624, Hungary
700    1_
$a Nagy, Lajos $u Department of Applied Chemistry, University of Debrecen, Debrecen, 4032, Hungary
700    1_
$a Kéki, Sándor $u Department of Applied Chemistry, University of Debrecen, Debrecen, 4032, Hungary
700    1_
$a Batta, Gyula $u Department of Organic Chemistry, University of Debrecen, Debrecen, 4032, Hungary
700    1_
$a Mitrović, Ana $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, 1000, Ljubljana, Slovenia
700    1_
$a Kos, Janko $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, 1000, Ljubljana, Slovenia $u Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia
700    1_
$a Zsigmond, Áron $u TargetEx Ltd., Dunakeszi, Madách Imre utca 31/2, 2120, Hungary
700    1_
$a Hajdú, István $u TargetEx Ltd., Dunakeszi, Madách Imre utca 31/2, 2120, Hungary
700    1_
$a Lőrincz, Zsolt $u TargetEx Ltd., Dunakeszi, Madách Imre utca 31/2, 2120, Hungary
700    1_
$a Bajusz, Dávid $u Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Magyar tudósok krt. 2, 1117, Hungary $1 https://orcid.org/http://orcid.org/0000000342779481
700    1_
$a Petri, László $u Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Magyar tudósok krt. 2, 1117, Hungary
700    1_
$a Hodek, Jan $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nam. 2, 16000, Prague 6, Czech Republic
700    1_
$a Jakab, Ferenc $u National Laboratory of Virology, University of Pécs, Pecs, Ifjúság útja 20, 7624, Hungary $u Faculty of Sciences, Institute of Biology, University of Pécs, Pecs, Ifjúság útja 6, 7624, Hungary
700    1_
$a Keserű, György M $u Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Magyar tudósok krt. 2, 1117, Hungary. keseru.gyorgy@ttk.hu
700    1_
$a Weber, Jan $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nam. 2, 16000, Prague 6, Czech Republic $1 https://orcid.org/http://orcid.org/0000000227997352
700    1_
$a Naesens, Lieve $u Rega Institute for Medical Research, KU Leuven, 3000, Leuven, Belgium. lieve.naesens@kuleuven.be
700    1_
$a Herczegh, Pál $u Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary
700    1_
$a Borbás, Anikó $u Department of Pharmaceutical Chemistry, University of Debrecen, Debrecen, Egyetem tér 1, 4032, Hungary. borbas.aniko@pharm.unideb.hu $u National Laboratory of Virology, University of Pécs, Pecs, Ifjúság útja 20, 7624, Hungary. borbas.aniko@pharm.unideb.hu
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 12, č. 1 (2022), s. 16001
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36163239 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100300 $b ABA008
999    __
$a ok $b bmc $g 1854207 $s 1175643
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c 1 $d 16001 $e 20220926 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a P4-0127 $p Javna Agencija za Raziskovalno Dejavnost RS (Slovenian Research Agency)
GRA    __
$a NKP- 21-5 $p Hungarian Academy of Sciences
GRA    __
$a 201832-30 and 202135-30 $p Fundació La Marató de TV3 (TV3 Marathon Foundation)
GRA    __
$a K 132870 $p Hungarian Scientific Research Fund
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace